

Neurocutaneous Disorder Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/N896981DE8D4EN.html>

Date: March 2022

Pages: 66

Price: US\$ 3,250.00 (Single User License)

ID: N896981DE8D4EN

Abstracts

The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord. These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late.

This report contains market size and forecasts of Neurocutaneous Disorder in Global, including the following market information:

Global Neurocutaneous Disorder Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Neurocutaneous Disorder market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Tuberous Sclerosis (TS) Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neurocutaneous Disorder include Pfizer, Johnson & Johnson, Medtronic, Abbott, Novartis, Roche, Sanofi, Takeda and Allergan, etc. In

2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurocutaneous Disorder companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neurocutaneous Disorder Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Neurocutaneous Disorder Market Segment Percentages, by Type, 2021 (%)

Tuberous Sclerosis (TS)

Neurofibromatosis (NF)

Sturge-Weber Syndrome

Von Hippel-Lindau (VHL)

Ataxia-Telangiectasia (A-T)

Others

Global Neurocutaneous Disorder Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Neurocutaneous Disorder Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Diagnostic Centers

Others

Global Neurocutaneous Disorder Market, By Region and Country, 2017-2022,
2023-2028 (\$ Millions)

Global Neurocutaneous Disorder Market Segment Percentages, By Region and
Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neurocutaneous Disorder revenues in global market, 2017-2022
(estimated), (\$ millions)

Key companies Neurocutaneous Disorder revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Johnson & Johnson

Medtronic

Abbott

Novartis

Roche

Sanofi

Takeda

Allergan

Syneron Medical

Aleva Neurotherapeutics

Abbott Laboratories

Bausch Health

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Neurocutaneous Disorder Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Neurocutaneous Disorder Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL NEUROCUTANEOUS DISORDER OVERALL MARKET SIZE

- 2.1 Global Neurocutaneous Disorder Market Size: 2021 VS 2028
- 2.2 Global Neurocutaneous Disorder Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Neurocutaneous Disorder Players in Global Market
- 3.2 Top Global Neurocutaneous Disorder Companies Ranked by Revenue
- 3.3 Global Neurocutaneous Disorder Revenue by Companies
- 3.4 Top 3 and Top 5 Neurocutaneous Disorder Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Neurocutaneous Disorder Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Neurocutaneous Disorder Players in Global Market
 - 3.6.1 List of Global Tier 1 Neurocutaneous Disorder Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Neurocutaneous Disorder Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Neurocutaneous Disorder Market Size Markets, 2021 & 2028

4.1.2 Tuberous Sclerosis (TS)

4.1.3 Neurofibromatosis (NF)

4.1.4 Sturge-Weber Syndrome

4.1.5 Von Hippel-Lindau (VHL)

4.1.6 Ataxia-Telangiectasia (A-T)

4.1.7 Others

4.2 By Type - Global Neurocutaneous Disorder Revenue & Forecasts

4.2.1 By Type - Global Neurocutaneous Disorder Revenue, 2017-2022

4.2.2 By Type - Global Neurocutaneous Disorder Revenue, 2023-2028

4.2.3 By Type - Global Neurocutaneous Disorder Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Neurocutaneous Disorder Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Diagnostic Centers

5.1.5 Others

5.2 By Application - Global Neurocutaneous Disorder Revenue & Forecasts

5.2.1 By Application - Global Neurocutaneous Disorder Revenue, 2017-2022

5.2.2 By Application - Global Neurocutaneous Disorder Revenue, 2023-2028

5.2.3 By Application - Global Neurocutaneous Disorder Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neurocutaneous Disorder Market Size, 2021 & 2028

6.2 By Region - Global Neurocutaneous Disorder Revenue & Forecasts

6.2.1 By Region - Global Neurocutaneous Disorder Revenue, 2017-2022

6.2.2 By Region - Global Neurocutaneous Disorder Revenue, 2023-2028

6.2.3 By Region - Global Neurocutaneous Disorder Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Neurocutaneous Disorder Revenue, 2017-2028

6.3.2 US Neurocutaneous Disorder Market Size, 2017-2028

6.3.3 Canada Neurocutaneous Disorder Market Size, 2017-2028

6.3.4 Mexico Neurocutaneous Disorder Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Neurocutaneous Disorder Revenue, 2017-2028

6.4.2 Germany Neurocutaneous Disorder Market Size, 2017-2028

6.4.3 France Neurocutaneous Disorder Market Size, 2017-2028

6.4.4 U.K. Neurocutaneous Disorder Market Size, 2017-2028

6.4.5 Italy Neurocutaneous Disorder Market Size, 2017-2028

6.4.6 Russia Neurocutaneous Disorder Market Size, 2017-2028

6.4.7 Nordic Countries Neurocutaneous Disorder Market Size, 2017-2028

6.4.8 Benelux Neurocutaneous Disorder Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Neurocutaneous Disorder Revenue, 2017-2028

6.5.2 China Neurocutaneous Disorder Market Size, 2017-2028

6.5.3 Japan Neurocutaneous Disorder Market Size, 2017-2028

6.5.4 South Korea Neurocutaneous Disorder Market Size, 2017-2028

6.5.5 Southeast Asia Neurocutaneous Disorder Market Size, 2017-2028

6.5.6 India Neurocutaneous Disorder Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Neurocutaneous Disorder Revenue, 2017-2028

6.6.2 Brazil Neurocutaneous Disorder Market Size, 2017-2028

6.6.3 Argentina Neurocutaneous Disorder Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Neurocutaneous Disorder Revenue, 2017-2028

6.7.2 Turkey Neurocutaneous Disorder Market Size, 2017-2028

6.7.3 Israel Neurocutaneous Disorder Market Size, 2017-2028

6.7.4 Saudi Arabia Neurocutaneous Disorder Market Size, 2017-2028

6.7.5 UAE Neurocutaneous Disorder Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer

7.1.1 Pfizer Corporate Summary

7.1.2 Pfizer Business Overview

7.1.3 Pfizer Neurocutaneous Disorder Major Product Offerings

7.1.4 Pfizer Neurocutaneous Disorder Revenue in Global Market (2017-2022)

7.1.5 Pfizer Key News

7.2 Johnson & Johnson

7.2.1 Johnson & Johnson Corporate Summary

- 7.2.2 Johnson & Johnson Business Overview
- 7.2.3 Johnson & Johnson Neurocutaneous Disorder Major Product Offerings
- 7.2.4 Johnson & Johnson Neurocutaneous Disorder Revenue in Global Market (2017-2022)
- 7.2.5 Johnson & Johnson Key News
- 7.3 Medtronic
 - 7.3.1 Medtronic Corporate Summary
 - 7.3.2 Medtronic Business Overview
 - 7.3.3 Medtronic Neurocutaneous Disorder Major Product Offerings
 - 7.3.4 Medtronic Neurocutaneous Disorder Revenue in Global Market (2017-2022)
 - 7.3.5 Medtronic Key News
- 7.4 Abbott
 - 7.4.1 Abbott Corporate Summary
 - 7.4.2 Abbott Business Overview
 - 7.4.3 Abbott Neurocutaneous Disorder Major Product Offerings
 - 7.4.4 Abbott Neurocutaneous Disorder Revenue in Global Market (2017-2022)
 - 7.4.5 Abbott Key News
- 7.5 Novartis
 - 7.5.1 Novartis Corporate Summary
 - 7.5.2 Novartis Business Overview
 - 7.5.3 Novartis Neurocutaneous Disorder Major Product Offerings
 - 7.5.4 Novartis Neurocutaneous Disorder Revenue in Global Market (2017-2022)
 - 7.5.5 Novartis Key News
- 7.6 Roche
 - 7.6.1 Roche Corporate Summary
 - 7.6.2 Roche Business Overview
 - 7.6.3 Roche Neurocutaneous Disorder Major Product Offerings
 - 7.6.4 Roche Neurocutaneous Disorder Revenue in Global Market (2017-2022)
 - 7.6.5 Roche Key News
- 7.7 Sanofi
 - 7.7.1 Sanofi Corporate Summary
 - 7.7.2 Sanofi Business Overview
 - 7.7.3 Sanofi Neurocutaneous Disorder Major Product Offerings
 - 7.7.4 Sanofi Neurocutaneous Disorder Revenue in Global Market (2017-2022)
 - 7.7.5 Sanofi Key News
- 7.8 Takeda
 - 7.8.1 Takeda Corporate Summary
 - 7.8.2 Takeda Business Overview
 - 7.8.3 Takeda Neurocutaneous Disorder Major Product Offerings

7.8.4 Takeda Neurocutaneous Disorder Revenue in Global Market (2017-2022)

7.8.5 Takeda Key News

7.9 Allergan

7.9.1 Allergan Corporate Summary

7.9.2 Allergan Business Overview

7.9.3 Allergan Neurocutaneous Disorder Major Product Offerings

7.9.4 Allergan Neurocutaneous Disorder Revenue in Global Market (2017-2022)

7.9.5 Allergan Key News

7.10 Syneron Medical

7.10.1 Syneron Medical Corporate Summary

7.10.2 Syneron Medical Business Overview

7.10.3 Syneron Medical Neurocutaneous Disorder Major Product Offerings

7.10.4 Syneron Medical Neurocutaneous Disorder Revenue in Global Market
(2017-2022)

7.10.5 Syneron Medical Key News

7.11 Aleva NeurOthersapeutics

7.11.1 Aleva NeurOthersapeutics Corporate Summary

7.11.2 Aleva NeurOthersapeutics Business Overview

7.11.3 Aleva NeurOthersapeutics Neurocutaneous Disorder Major Product Offerings

7.11.4 Aleva NeurOthersapeutics Neurocutaneous Disorder Revenue in Global Market
(2017-2022)

7.11.5 Aleva NeurOthersapeutics Key News

7.12 Abbott Laboratories

7.12.1 Abbott Laboratories Corporate Summary

7.12.2 Abbott Laboratories Business Overview

7.12.3 Abbott Laboratories Neurocutaneous Disorder Major Product Offerings

7.12.4 Abbott Laboratories Neurocutaneous Disorder Revenue in Global Market
(2017-2022)

7.12.5 Abbott Laboratories Key News

7.13 Bausch Health

7.13.1 Bausch Health Corporate Summary

7.13.2 Bausch Health Business Overview

7.13.3 Bausch Health Neurocutaneous Disorder Major Product Offerings

7.13.4 Bausch Health Neurocutaneous Disorder Revenue in Global Market
(2017-2022)

7.13.5 Bausch Health Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neurocutaneous Disorder Market Opportunities & Trends in Global Market

Table 2. Neurocutaneous Disorder Market Drivers in Global Market

Table 3. Neurocutaneous Disorder Market Restraints in Global Market

Table 4. Key Players of Neurocutaneous Disorder in Global Market

Table 5. Top Neurocutaneous Disorder Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Neurocutaneous Disorder Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Neurocutaneous Disorder Revenue Share by Companies, 2017-2022

Table 8. Global Companies Neurocutaneous Disorder Product Type

Table 9. List of Global Tier 1 Neurocutaneous Disorder Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Neurocutaneous Disorder Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Neurocutaneous Disorder Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Neurocutaneous Disorder Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Neurocutaneous Disorder Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Neurocutaneous Disorder Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Neurocutaneous Disorder Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Neurocutaneous Disorder Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Neurocutaneous Disorder Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Neurocutaneous Disorder Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Neurocutaneous Disorder Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Neurocutaneous Disorder Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Neurocutaneous Disorder Revenue, (US\$, Mn),

2017-2022

Table 23. By Country - Europe Neurocutaneous Disorder Revenue, (US\$, Mn),
2023-2028

Table 24. By Region - Asia Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Neurocutaneous Disorder Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Neurocutaneous Disorder Revenue, (US\$, Mn),
2017-2022

Table 27. By Country - South America Neurocutaneous Disorder Revenue, (US\$, Mn),
2023-2028

Table 28. By Country - Middle East & Africa Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Neurocutaneous Disorder Revenue, (US\$, Mn), 2023-2028

Table 30. Pfizer Corporate Summary

Table 31. Pfizer Neurocutaneous Disorder Product Offerings

Table 32. Pfizer Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)

Table 33. Johnson & Johnson Corporate Summary

Table 34. Johnson & Johnson Neurocutaneous Disorder Product Offerings

Table 35. Johnson & Johnson Neurocutaneous Disorder Revenue (US\$, Mn),
(2017-2022)

Table 36. Medtronic Corporate Summary

Table 37. Medtronic Neurocutaneous Disorder Product Offerings

Table 38. Medtronic Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)

Table 39. Abbott Corporate Summary

Table 40. Abbott Neurocutaneous Disorder Product Offerings

Table 41. Abbott Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)

Table 42. Novartis Corporate Summary

Table 43. Novartis Neurocutaneous Disorder Product Offerings

Table 44. Novartis Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)

Table 45. Roche Corporate Summary

Table 46. Roche Neurocutaneous Disorder Product Offerings

Table 47. Roche Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)

Table 48. Sanofi Corporate Summary

Table 49. Sanofi Neurocutaneous Disorder Product Offerings

Table 50. Sanofi Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)

Table 51. Takeda Corporate Summary

Table 52. Takeda Neurocutaneous Disorder Product Offerings

Table 53. Takeda Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)

Table 54. Allergan Corporate Summary

Table 55. Allergan Neurocutaneous Disorder Product Offerings
Table 56. Allergan Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)
Table 57. Syneron Medical Corporate Summary
Table 58. Syneron Medical Neurocutaneous Disorder Product Offerings
Table 59. Syneron Medical Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)
Table 60. Aleva NeuroOthersapeutics Corporate Summary
Table 61. Aleva NeuroOthersapeutics Neurocutaneous Disorder Product Offerings
Table 62. Aleva NeuroOthersapeutics Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)
Table 63. Abbott Laboratories Corporate Summary
Table 64. Abbott Laboratories Neurocutaneous Disorder Product Offerings
Table 65. Abbott Laboratories Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)
Table 66. Bausch Health Corporate Summary
Table 67. Bausch Health Neurocutaneous Disorder Product Offerings
Table 68. Bausch Health Neurocutaneous Disorder Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Neurocutaneous Disorder Segment by Type in 2021
- Figure 2. Neurocutaneous Disorder Segment by Application in 2021
- Figure 3. Global Neurocutaneous Disorder Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Neurocutaneous Disorder Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Neurocutaneous Disorder Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Neurocutaneous Disorder Revenue in 2021
- Figure 8. By Type - Global Neurocutaneous Disorder Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Neurocutaneous Disorder Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Neurocutaneous Disorder Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Neurocutaneous Disorder Revenue Market Share, 2017-2028
- Figure 12. US Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Neurocutaneous Disorder Revenue Market Share, 2017-2028
- Figure 16. Germany Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Neurocutaneous Disorder Revenue Market Share, 2017-2028
- Figure 24. China Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028
- Figure 28. India Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Neurocutaneous Disorder Revenue Market Share, 2017-2028

Figure 30. Brazil Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Neurocutaneous Disorder Revenue Market Share, 2017-2028

Figure 33. Turkey Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Neurocutaneous Disorder Revenue, (US\$, Mn), 2017-2028

Figure 37. Pfizer Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Johnson & Johnson Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Medtronic Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Abbott Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Novartis Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Roche Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Sanofi Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Takeda Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Allergan Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Syneron Medical Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Aleva NeuroOthersapeutics Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Abbott Laboratories Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Bausch Health Neurocutaneous Disorder Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Neurocutaneous Disorder Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/N896981DE8D4EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N896981DE8D4EN.html>